ACE OncoCast

Enrique Grande, MD, MSc, PhD   Quirónsalud Madrid Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the...

Francisco X. Real, MD, PhD National Cancer Research Center Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throu...

Félix Guerrero-Ramos, MD, PhD, FEBU Hospital Doce de Octubre Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients thr...

Natalia Carballo, MD Sanitas Hospitals/Atrys Health Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout t...

Félix Guerrero-Ramos, MD, PhD, FEBU Hospital Doce de Octubre Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the...

Natalia Carballo, MD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course...

Enrique Grande, MD, MSc, PhD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the...

Francisco X. Real, MD, PhD National Cancer Research Center Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the co...

Episode 1: Opening & Keynote Speech: First-line treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) Enrique Grande, MD, MSc, PhD The therapeutic landscape of unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) has undergone a significant transformation in recent years with the addition of immune checkpoint inhibitors (IC...

Episode 2: Case 1: First-line treatment with maintenance immunotherapy for a platinum-eligible patient Case 2: First-line treatment with mono-immunotherapy for a cisplatin-ineligible patient Joachim Chan, BSc, MBBS, MRCP, FRCR, MD The therapeutic landscape of unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) has undergone a significant transformation in recent years with th...

Episode 3: Panel Discussion & Pearls for Practice Fernando Maluf, MD, PhD, Enrique Grande, MD, MSc, PhD and Joachim Chan, BSc, MBBS, MRCP, FRCR, MD The therapeutic landscape of unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) has undergone a significant transformation in recent years with the addition of immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and nove...

Episode 1: Opening & Keynote Speech: Second-line and salvage treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) Philippe Barthélémy, MD, PhD The increasing availability of treatment options in the first-line (1L) setting after ESMO 2023 has led to a growing complexity in determining sequential treatment strategies for different clinical scen...

Episode 2: Case 1: Second-line and salvage treatment options after maintenance immunotherapy Case 2: Second-line and salvage treatment options after platinum-based chemotherapy Kate Smith, MBBS, MRCP, MD, PhD The increasing availability of treatment options in the first-line (1L) setting after ESMO 2023 has led to a growing complexity in determining sequential treatment strategies for different cl...

Episode 3: Panel Discussion & Pearls for Practice Aristotelis Bamias, MD, PhD, Philippe Barthélémy, MD, PhD and Kate Smith, MBBS, MRCP, MD, PhD The increasing availability of treatment options in the first-line (1L) setting after ESMO 2023 has led to a growing complexity in determining sequential treatment strategies for different clinical scenarios following progression of 1L therapies. In th...

The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armamentarium. In this Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer, experts in the field will di...

The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armamentarium. In this Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer, experts in the field will di...

The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armamentarium. In this Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer, experts in the field will di...

The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armamentarium. In this Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer, experts in the field will di...

About 70% to 80% of bladder cancers present as non-muscle-invasive bladder cancer (NMIBC). The management of NMIBC includes transurethral resection of bladder tumor (TURBT), followed by single-dose intravesical immunotherapy with bacille Calmette-Guérin (BCG) or intravesical chemotherapy (mitomycin C, epirubicin, or doxorubicin). The decision to instill BCG and/or chemotherapy is based on the risk...

Muscle-Invasive Bladder Cancer (MIBC) is defined as the tumor has spread through the bladder lining and into the bladder muscle. Optimal treatment strategies for MIBC requires the involvement of a specialist multidisciplinary team (MDT), with collaboration between surgeons, medical oncologists, radiation oncologists, pathologists and other specialists. Bladder preservation is an alternative to cys...

There is a steadily widening range of second-line (2L) and subsequent treatment options for patients with advanced UC including chemotherapy, immune checkpoint inhibitors (ICIs) and novel therapies. In recent years, ICIs have predominantly replaced chemotherapy as the preferred 2L treatment. Furthermore, antibody-drug conjugates (ADC) and targeted agents have become available. The selection of 2L...

Platinum-based chemotherapy (CT) has been the preferred treatment for patients with unresectable locally advanced and/or metastatic (LA/m) urothelial cancer (UC) for several decades. With the evolving development of immunotherapy in the first-line (1L) setting, the standard management approach for LA/m UC consisted of cisplatin-based CT in cisplatin eligible patients or carboplatin-based CT in cis...

In this first of three podcasts on extensive-stage SCLC, the experts discuss the management of patients with relapsed SCLC based on current evidence and guidelines.

In the second podcast on extensive-stage SCLC, the experts examine the biology of SCLC and discuss the molecular subtypes, which have distinct therapeutic vulnerabilities. 

In the third and final podcast on extensive-stage SCLC, the experts discuss ongoing trials, as well as potential predictive biomarkers of response, and the problem of tumor plasticity.